TG Therapeutics, Inc. (NASDAQ: TGTX) announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE